Blair William & Co. IL Boosts Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Blair William & Co. IL increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,443 shares of the company's stock after purchasing an additional 1,875 shares during the quarter. Blair William & Co. IL's holdings in Krystal Biotech were worth $1,166,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in KRYS. BNP Paribas Financial Markets boosted its position in Krystal Biotech by 346.8% in the third quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company's stock worth $1,899,000 after purchasing an additional 8,098 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Krystal Biotech by 3.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock worth $840,000 after purchasing an additional 153 shares during the period. Hilltop Holdings Inc. purchased a new position in shares of Krystal Biotech in the 3rd quarter worth about $209,000. State Street Corp grew its position in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after buying an additional 119,936 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Krystal Biotech by 15.1% during the third quarter. Wellington Management Group LLP now owns 12,680 shares of the company's stock worth $2,308,000 after buying an additional 1,660 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Remove Ads

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded down $5.29 during trading on Monday, hitting $166.01. 515,569 shares of the company were exchanged, compared to its average volume of 292,974. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The stock has a 50 day moving average of $173.40 and a 200 day moving average of $172.87. The company has a market cap of $4.78 billion, a PE ratio of 55.52 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 EPS. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on KRYS shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $220.00.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).